A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex [CDB 4124; Repros Therapeutics] in the Treatment of Premenopausal Women With Symptomatic Endometriosis.

Trial Profile

A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex [CDB 4124; Repros Therapeutics] in the Treatment of Premenopausal Women With Symptomatic Endometriosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Endometriosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 14 Aug 2009 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Planned end date changed from 1 Feb 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top